1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Cochlear Limited

Cochlear Limited

CHEOY
Cochlear LimitedUS flagOther OTC
33.92
USD
-1.14
- -
4.44BMarket Cap
Cochlear Limited
CHEOY
(Other OTC)

Recent

price

33.92

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
6.53
7.15
6.85
6.62
7.07
8.13
9.89
10.92
11.85
12.37
11.07
11.39
12.53
14.72
17.06
17.9
Revenue per Share
1.38
1.59
0.5
1.17
0.82
1.28
1.65
1.95
2.14
2.4
-2
2.48
2.2
2.29
2.72
2.97
Basic EPS, GAAP
0.77
0.98
1.15
0.17
0.7
1.41
1.29
1.64
-0.43
-0.99
-1.09
-0.55
-0.59
-0.73
-0.69
-0.78
Free Cash Flow per Basic Share
0.95
1.05
1.2
1.25
1.27
1.09
1.05
1.25
1.4
1.58
1.62
0.58
1.47
1.5
1.87
2.13
Dividend per Share
3.72
4.27
3.58
3.5
3.17
3.35
4.05
4.85
5.6
6.42
11.64
12.5
13.17
13.73
14.28
14.92
Book Value per Share
2.01
2.6
1.57
1.06
0.84
1.11
1.96
1.77
2.31
2.61
8.31
9.88
9.83
9.92
10.6
11.08
Tangible Book Value per Share
113
113
114
114
114
114
114
115
115
115
119
131
132
132
131
131
Basic Weighted Avg Shares
735
810
779
753
805
926
1,131
1,254
1,364
1,427
1,321
1,498
1,648
1,936
2,236
2,343
Sales/Revenue/Turnover
29.45
29.52
16.27
21.93
12.52
18.55
19.01
22.33
22.45
21.52
11.34
15.49
17.95
16.11
18.52
17.33
Operating Margin (%)
- -
- -
16
15
27
30
33
31
34
38
78
80
73
81
85
90
Depreciation Expense
155
180
57
133
94
146
189
224
246
277
-238
326
289
301
357
389
Net Income, GAAP
25.89
23.4
21.28
23.21
19.98
25.71
25.7
27.59
27.81
24.32
- -
10.72
26.59
24.21
26.4
25
Effective Tax Rate (%)
21.11
22.25
7.29
17.61
11.64
15.76
16.71
17.83
18.02
19.39
-18.04
21.8
17.54
15.53
15.96
16.6
Profit Margin (%)
235
206
112
213
251
86
280
137
287
276
660
828
799
784
821
814
Working Capital
83
3
20
167
234
45
189
134
144
178
285
232
175
163
202
194
LT Debt
438
503
385
357
329
355
449
544
611
726
1,402
1,702
1,686
1,749
1,840
1,950
Total Equity
27.52
30.74
18.94
25.26
14.56
21.93
25.67
26.51
26.72
26.97
- -
10.12
11.04
12.05
14.97
14.12
Return on Invested Capital (%)
29.07
33.29
12.1
26.48
17.46
25.74
31.26
30.21
30.49
32.73
- -
16.85
15.17
15.41
17.63
18.45
Return on Capital (%)
39.5
39.92
12.77
32.93
24.66
39.26
44.73
43.86
40.93
39.93
-22.38
21.53
17.13
16.99
19.4
20.33
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.71%
7.09%
5.97%
Free Cash Flow
3.21%
-1.18%
14.25%
Net Income, GAAP
-33.25%
-43.36%
9%
Sales/Revenue/Turnover
10.02%
12.24%
4.81%
Total Cash Common Dividend
18.32%
27.02%
13.23%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1,936
2024
- -
- -
- -
- -
2,236
2025
- -
- -
- -
- -
2,343

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2.29
2024
- -
- -
- -
- -
2.72
2025
- -
- -
- -
- -
2.97

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.5
2024
- -
- -
- -
- -
1.87
2025
- -
- -
- -
- -
2.13
Similar Companies
Ypsomed Holding AG (0QLQ.L)
TriSalus Life Sciences, Inc. (TLSI)
EL.En. S.p.A. (ELN.MI)
Medtronic plc (0Y6X.L)
Create Medic Co., Ltd. (5187.T)
Catheter Precision, Inc. (VTAK)
Business
Cochlear Limited is a global leader in the design, manufacture, and sale of implantable hearing solutions. The company’s core products include cochlear implants, bone conduction implants, acoustic implants, and associated sound processors, accessories, and wireless communication devices. Cochlear offers a range of hearing solutions under prominent brands such as Nucleus®, Baha®, and Osia®, targeting individuals with moderate to profound hearing loss. The company operates primarily in the healthcare industry, focusing on medical devices and hearing implant technology. Cochlear’s products are distributed and supported in markets worldwide, including North America, Europe, Asia-Pacific, and Latin America. Founded in 1981, Cochlear Limited is headquartered in Sydney, Australia. Recent major developments for Cochlear include strategic expansions in product offerings and partnerships aimed at enhancing hearing healthcare. Over the last 1-2 years, Cochlear has introduced new advanced implant technologies and sound processors that integrate with digital and wireless technologies to improve user experience. The company has strengthened its global commercial presence through partnerships with hearing healthcare providers and has focused investments on research and development for next-generation hearing technologies. Additionally, Cochlear continues to expand its service offerings for post-implant care and rehabilitation support, consolidating its position as a comprehensive hearing solutions provider. Cochlear operates through multiple business segments covering product development, manufacturing, distribution, and aftercare services. Its target market encompasses healthcare professionals, audiologists, and individuals with hearing impairment, with an emphasis on accessibility and technology innovation across diverse geographic regions. Subsidiaries and affiliates operate internationally, supporting Cochlear's global supply chain and customer service capabilities. The company remains committed to advancing hearing implant technology through continued innovation and strategic growth initiatives.

Company News

APIChat

  • prnewswire.com

    Better Hearing and Whole-Body Health: What to Know About MRI Access with Cochlear Implants

  • newsfilecorp.com

    Envoy Medical Reports Landmark Accomplishments, Advancing Toward FDA Approval of First-of-Its-Kind Fully Implanted Cochlear Implant

  • businesswire.com

    MED-EL USA Presents Real World Clinical Insights to Support Tailored Hearing Solutions at the 2026 American Cochlear Implant Association Meeting

  • seekingalpha.com

    Cochlear Limited (CHEOY) Q3 2026 Sales/Trading Call Transcript

  • reuters.com

    Australia's Cochlear crashes 40% after flagging weak demand and Mideast war impact

  • defenseworld.net

    Head-To-Head Survey: DocGo (NASDAQ:DCGO) vs. CochLear (OTCMKTS:CHEOY)

  • newsfilecorp.com

    Envoy Medical Announces First Patients Successfully Reaching 12-Month Endpoint in Pivotal Clinical Trial for Fully Implanted Cochlear Implant

  • newsfilecorp.com

    Envoy Medical Completes Enrollment of Pivotal Clinical Trial Evaluating First-Of-Its-Kind Fully Implanted Cochlear Implant

  • defenseworld.net

    CochLear (OTCMKTS:CHEOY) and Sonic Healthcare (OTCMKTS:SKHHY) Financial Review

  • prnewswire.com

    Cochlear North America Celebrates International Cochlear Implant Day with Announcement of 2026 Academic Scholarship Recipients

  • seekingalpha.com

    Cochlear Limited (CHEOY) Q2 2026 Earnings Call Transcript

  • prnewswire.com

    Cochlear Announces Availability of Nucleus Nexa System to US Military Veterans

  • defenseworld.net

    CochLear (OTCMKTS:CHEOY) versus Biodesix (NASDAQ:BDSX) Head-To-Head Review

  • globenewswire.com

    MRI 3T Cochlear Implant Market Poised for 9.96% CAGR Growth, North America Leads

  • businesswire.com

    MED-EL Cochlear Implant Becomes First FDA-Approved Option for Children Seven Months and Older

  • newsfilecorp.com

    Envoy Medical Secures New U.S. Patent for Innovative Cochlear Implant System Featuring a Removable Earplug Sensor and an Implanted Battery

  • newsfilecorp.com

    Envoy Medical Marks Three-Year Anniversary of First Patient Receiving Its Breakthrough Fully Implanted Cochlear Implant

  • newsfilecorp.com

    Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology

  • newsfilecorp.com

    Envoy Medical Successfully Reaches Three-Month Follow-Up Milestone in Clinical Trial of the Acclaim Fully Implanted Cochlear Implant

  • seekingalpha.com

    Cochlear Limited (CHEOF) Q4 2025 Earnings Call Transcript